Asunto(s)
Pruebas de Función de la Tiroides , Glándula Tiroides , Humanos , Bélgica , Tiroxina , Triyodotironina , TirotropinaRESUMEN
Women with thyroid autoimmunity (TAI), predominately characterized by increased levels of thyroid peroxidase antibody (TPOAb), are at risk for developing pregnancy related complications. In this review, we discuss the importance of TAI during natal and perinatal stages. Before pregnancy, TAI is associated with higher mean serum TSH levels and certain causes of subfertility. During pregnancy, TAI increases the risk of an insufficient response of the thyroid to an increasing strain induced by pregnancy, and consequently (subclinical) hypothyroidism might develop. Euthyroid women with TAI have a higher rate of maternal and foetal complications, but it seems that causality cannot be pinned down to thyroid dysfunction alone. Almost half of the women known with TAI prior to pregnancy will also develop post-partum thyroiditis (PPT). However, any relation between PPT and post-partum depression remains uncertain. More research is required to explain possible associations between TAI and pregnancy morbidities, and studies should focus on a better understanding of TAI as such. Given the many unanswered questions, at present, it is not recommended to screen all (potentially) pregnant women for the presence of TAI.
Asunto(s)
Hipotiroidismo , Complicaciones del Embarazo , Enfermedades de la Tiroides , Femenino , Embarazo , Humanos , Autoinmunidad , Hipotiroidismo/complicaciones , Autoanticuerpos , Enfermedades de la Tiroides/complicacionesRESUMEN
BACKGROUND: Hypothyroidism is a topic that continues to provoke debate and controversy with regards to specific indications, type of thyroid hormone substitution and efficacy. We investigated the use of thyroid hormones in clinical practice in Belgium, a country where currently only levothyroxine (LT4) tablet formulations are available. METHOD: Members of the Belgian Endocrine Society were invited to respond to an online questionnaire. Results were compared with those from other THESIS surveys. RESULTS: Eighty (50%) of the invited 160 individuals, completed the questionnaire. LT4 was the first treatment of choice for all respondents. As secondary choice, some also prescribed liothyronine (LT3) and LT4 + LT3 combinations (2 and 7 respondents, respectively). Besides hypothyroidism, 34 and 50% of respondents used thyroid hormones for infertile euthyroid TPOAb positive women and the treatment of a growing non-toxic goiter, respectively. Had alternative formulations of LT4 to tablets been available (soft gel or liquid L-T4), 2 out of 80 (2.5%) participants would consider them for patients achieving biochemical euthyroidism but remaining symptomatic. This proportion was higher in case of unexplained poor biochemical control of hypothyroidism (13.5%) and in patients with celiac disease or malabsorption or interfering drugs (10%). In symptomatic euthyroid patients, 20% of respondents would try combined LT4 + LT3 treatment. Psychosocial factors were highlighted as the main contributors to persistent symptoms. CONCLUSIONS: LT4 tablets is the preferred treatment for hypothyroidism in Belgium. A minority of the respondents would try combined LT4 + LT3 in symptomatic but biochemically euthyroid patients. Thyroid hormones are prescribed for euthyroid infertile women with thyroid autoimmunity and patients with non-toxic goiter, a tendency noted in other European countries, despite current evidence of lack of benefit.
RESUMEN
SUMMARY: The pandemic caused by severe acute respiratory syndrome coronavirus 2 is of an unprecedented magnitude and has made it challenging to properly treat patients with urgent or rare endocrine disorders. Little is known about the risk of coronavirus disease 2019 (COVID-19) in patients with rare endocrine malignancies, such as pituitary carcinoma. We describe the case of a 43-year-old patient with adrenocorticotrophic hormone-secreting pituitary carcinoma who developed a severe COVID-19 infection. He had stabilized Cushing's disease after multiple lines of treatment and was currently receiving maintenance immunotherapy with nivolumab (240 mg every 2 weeks) and steroidogenesis inhibition with ketoconazole (800 mg daily). On admission, he was urgently intubated for respiratory exhaustion. Supplementation of corticosteroid requirements consisted of high-dose dexamethasone, in analogy with the RECOVERY trial, followed by the reintroduction of ketoconazole under the coverage of a hydrocortisone stress regimen, which was continued at a dose depending on the current level of stress. He had a prolonged and complicated stay at the intensive care unit but was eventually discharged and able to continue his rehabilitation. The case points out that multiple risk factors for severe COVID-19 are present in patients with Cushing's syndrome. 'Block-replacement' therapy with suppression of endogenous steroidogenesis and supplementation of corticosteroid requirements might be preferred in this patient population. LEARNING POINTS: Comorbidities for severe coronavirus disease 2019 (COVID-19) are frequently present in patients with Cushing's syndrome. 'Block-replacement' with suppression of endogenous steroidogenesis and supplementation of corticosteroid requirements might be preferred to reduce the need for biochemical monitoring and avoid adrenal insufficiency. The optimal corticosteroid dose/choice for COVID-19 is unclear, especially in patients with endogenous glucocorticoid excess. First-line surgery vs initial disease control with steroidogenesis inhibitors for Cushing's disease should be discussed depending on the current healthcare situation.
RESUMEN
Severe thyroid dysfunction may lead to menstrual disorders and subfertility. Fertility problems may persist even after restoring normal thyroid function, and then an assisted reproductive technology (ART) may be a solution. Prior to an ART treatment, ovarian stimulation is performed, leading to high oestradiol levels, which may lead to hypothyroidism in women with thyroid autoimmunity (TAI), necessitating levothyroxine (LT4) supplements before pregnancy. Moreover, women with the polycystic ovarian syndrome and idiopathic subfertility have a higher prevalence of TAI. Women with hypothyroidism treated with LT4 prior to ART should have a serum TSH level <2.5 mIU/L. Subfertile women with hyperthyroidism planning an ART procedure should be informed of the increased risk of maternal and foetal complications, and euthyroidism should be restored and maintained for several months prior to an ART treatment. Fertilisation rates and embryo quality may be impaired in women with TSH >4.0 mIU/L and improved with LT4 therapy. In meta-analyses that mainly included women with TSH levels >4.0 mIU/L, LT4 treatment increased live birth rates, but that was not the case in 2 recent interventional studies in euthyroid women with TAI. The importance of the increased use of intracytoplasmic sperm injection as a type of ART on pregnancy outcomes in women with TAI deserves more investigation. For all of the above reasons, women of subfertile couples should be screened routinely for the presence of thyroid disorders.
RESUMEN
The aim of this study is to assess differences in patient characteristics, tumour characteristics and hormone levels between acromegalic patients with and without hyperprolactinemia. 44 patients of the University Hospital of Brussels, Belgium with acromegaly who were diagnosed between January 2007 and July 2018 were included in this study. Nineteen patients were classified in the hyperprolactinemia group and 25 patients were classified in the normoprolactinemia group. No significant differences between acromegalic patients with and without hyperprolactinemia were found in age at diagnosis, gender, presence of hyperprolactinemia symptoms, insulin-like growth factor 1, growth hormone and testosterone levels, tumour volume, tumour invasiveness, immunohistochemistry of growth hormone and prolactin, Ki-67 index and mitotic index. However, for a cut-off of 10% of prolactin-positive cells, there was a trend towards a higher percentage of prolactin-positive tumours in hyperprolactinemia patients (p=0.054) and higher mean prolactin level in case of positive prolactin immunostaining (p=0.007)). In our study there were no differences in characteristics between acromegaly patients with hyper- and normoprolactinemia. An association between the serum prolactin level and the positivity of prolactin immunohistochemistry of the adenoma tissue was found. The absence of a difference in tumour volume between patients with hyper- and normoprolactinemia suggests that the hyperprolactinemia is likely to be caused by the co-secretion of growth hormone and prolactin by the tumour. Finally, for the first time, the cut-off of 10% of prolactin cells was validated for the diagnosis of somatolactotroph tumours in acromegaly.
Asunto(s)
Acromegalia/complicaciones , Adenoma/patología , Hiperprolactinemia/patología , Neoplasias Hipofisarias/patología , Prolactina/sangre , Adenoma/sangre , Estudios Transversales , Femenino , Humanos , Hiperprolactinemia/sangre , Hiperprolactinemia/etiología , Masculino , Persona de Mediana Edad , Neoplasias Hipofisarias/sangre , Pronóstico , Estudios RetrospectivosRESUMEN
BACKGROUND: Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we thought to investigate possible predictive factors of pharmacological resistance of prolactinomas to dopamine agonists. METHODS: We retrospectively analyzed a database of a Belgian tertiary reference center for patients with pituitary tumours from 2014 to 2016. The groups of interest were patients with dopamine agonist responsive and resistant prolactinomas. The possible predictive factors, including MRI findings, endocrinological parameters, response of tumour and patient factors for dopamine agonist resistance were investigated. RESULTS: We included 69 patients of whom 52 were women (75,4%) and 17 were men (24,6%). Rate of dopamine agonist resistance was 15.9%. We identified four significant predictors of dopamine agonist resistance: male gender, a large tumour volume, prolonged time to prolactin normalization and presence of a cystic, hemorrhagic and/or necrotic component. In addition, symptoms due to mass effect, high baseline prolactin level and a high contrast capture on MRI are factors that can be taken into consideration. CONCLUSION: We identified predictive factors for pharmacological resistance and developed a scoring system for patient specific prediction of resistance to dopamine agonists. This scoring system may have impact on the timing and decision of surgery in prolactinoma patients after further prospective evaluation.
Asunto(s)
Agonistas de Dopamina/uso terapéutico , Neoplasias Hipofisarias/sangre , Neoplasias Hipofisarias/tratamiento farmacológico , Prolactina/sangre , Prolactinoma/sangre , Prolactinoma/tratamiento farmacológico , Adulto , Anciano , Bélgica/epidemiología , Cabergolina/uso terapéutico , Resistencia a Medicamentos/efectos de los fármacos , Resistencia a Medicamentos/fisiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Hipofisarias/diagnóstico por imagen , Valor Predictivo de las Pruebas , Prolactinoma/diagnóstico por imagen , Estudios Retrospectivos , Centros de Atención Terciaria , Adulto JovenRESUMEN
Thyroid autoimmunity (TAI) and/or thyroid dysfunction are prevalent in women of reproductive age and have independently been associated with adverse fertility and pregnancy outcomes, in the case of spontaneous conception or after assisted reproductive technology (ART). Thus, it seems reasonable to screen for thyrotropin (TSH) and thyroid peroxidase autoantibodies (TPO-abs) in infertile women attempting pregnancy. However, even if the relationship between fertility and thyroid dysfunction and/or TAI persists when properly controlled for other variables, it remains challenging to claim causation. Several studies with different designs (cross sectional, case -control, prospective and retrospective cohort studies) have looked at the association between thyroid autoimmunity, thyroid function and fertility. Heterogeneity among study results are related to small numbers of included patients, poor study design, selection of causes of infertility and different assays used to measure TAI, thyroid hormones and TSH reference values. Indeed, there is no consensus regarding the upper limit of normal for TSH to define thyroid dysfunction and the cut-off levels for intervention. Furthermore, data from interventional trials looking at the impact of levothyroxine treatment on fertility outcome in randomised controlled studies are scarce. Despite the recent update of the guidelines by the American Thyroid Association (ATA) for the Diagnosis and Management of Thyroid Disease during Pregnancy and the postpartum, many questions remain unsettled in ART.
Asunto(s)
Infertilidad Femenina/etiología , Infertilidad Femenina/terapia , Resultado del Embarazo , Técnicas Reproductivas Asistidas , Enfermedades de la Tiroides/complicaciones , Enfermedades de la Tiroides/terapia , Adulto , Femenino , Fertilidad/fisiología , Humanos , Infertilidad Femenina/diagnóstico , Infertilidad Femenina/epidemiología , Embarazo , Resultado del Embarazo/epidemiología , Diagnóstico Prenatal/métodos , Técnicas Reproductivas Asistidas/efectos adversos , Enfermedades de la Tiroides/epidemiología , Pruebas de Función de la Tiroides , Resultado del TratamientoRESUMEN
INTRODUCTION: A 26-year-old female presented with severe hypercalcemia. She was asymptomatic. Blood analysis revealed high serum calcium (13 mg/dL = 3.25 mmol/L) and elevated intact parathyroid hormone (iPTH) levels (267.5 ng/L). RESULTS: Ultrasonography showed a mixed solid-cystic nodule of 30 mm in the left thyroid lower lobe and a nodular lesion of 14 mm posterior of the thyroid upper pole suggestive for parathyroid adenoma. Sestamibi scan and magnetic resonance imaging (MRI) revealed hyperfunctioning parathyroid tissue posterior of the left thyroid upper lobe. During surgery, a 15 mm nodule in the usual location of the left superior parathyroid was resected. Intraoperative frozen section revealed normal parathyroid tissue and intraoperative PTH levels did not decrease. Left thyroidectomy was performed due to the large solid-cystic nodule. Intraoperative PTH levels normalized 10 min later. Pathologic examination revealed a 28 mm nodule in the lower thyroid pole compatible with a parathyroid carcinoma (PC). Due to positive margins, a completion thyroidectomy was performed. 5-year follow-up showed no recurrence. CONCLUSIONS: PC is a rare entity comprising 0.5-2% of patients with primary hyperparathyroidism. Even more unusual is an intrathyroidal parathyroid gland (0.2%). Only a dozen cases of intrathyroidal PC have been reported. Our case is the second patient reported to be asymptomatic.
Asunto(s)
Carcinoma/diagnóstico , Coristoma/diagnóstico , Hipercalcemia/etiología , Glándulas Paratiroides , Neoplasias de las Paratiroides/diagnóstico , Enfermedades de la Tiroides/diagnóstico , Adulto , Femenino , HumanosRESUMEN
Hypoparathyroidism is a rare endocrine disease with insufficient parathyroid hormone levels. Replacing the missing hormone is not yet a standard therapy. The objective of this retrospective cohort study was to evaluate if the usual therapy regimens of postsurgical hypoparathyroidism with calcitriol have a negative effect on renal function. We performed a chart analysis of patients who were seen in a tertiary care hospital in Brussels, Belgium. A total of 101 subjects were identified as patients with permanent post-surgical hypoparathyroidism, based on the hospital records of patients who underwent a total thyroidectomy between 1996 and 2016, while still being treated with calcitriol. Patients with pre-existing renal insufficiency and/or active malignancy were excluded. The cohort was predominantly female of Caucasian origin. Renal function was evaluated before and after surgery (with a maximum follow-up of 12 years), using the CKD-EPI equation. A multivariate linear regression model was used to correlate renal function decline with the duration of calcitriol therapy, while correcting for the mean calcium phosphate product and age. We found a statistically significant (p=0.027) relationship between the duration of calcitriol treatment and renal function decline at a rate of 1.06 ml/min/1.73 m2 per year of calcitriol therapy. Our study, although being retrospective, is the first one to demonstrate a relationship between the cumulative use of calcitriol therapy and renal function decline.
Asunto(s)
Calcitriol/efectos adversos , Agonistas de los Canales de Calcio/efectos adversos , Tasa de Filtración Glomerular , Hipoparatiroidismo/cirugía , Complicaciones Posoperatorias/tratamiento farmacológico , Insuficiencia Renal/inducido químicamente , Tiroidectomía/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Pruebas de Función Renal , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/etiología , Pronóstico , Estudios Retrospectivos , Factores de Tiempo , Adulto JovenRESUMEN
OBJECTIVE: To predict the impact of thyroid autoimmunity (TAI) on the probability of delivery after a defined number of treatment cycles, using analysis of cumulative delivery rates in patients with and without TAI. DESIGN: Retrospective cohort study performed at the Center for Reproductive Medicine and Department of Endocrinology, University Hospital of Brussels, approved by the institutional review board of the hospital. SETTING: University hospital. PATIENT(S): All patients who started their first IVF/intracytoplasmic sperm injection cycle at our fertility center between January 1, 2010 and December 31, 2011 were included. MAIN OUTCOME MEASURE(S): Live birth delivery after 25 weeks' gestation was taken as the primary endpoint of our study Cumulative delivery rates were calculated for both groups until six treatment cycles. INTERVENTION(S): All patients (in both groups) received the usual IVF treatment protocols (i.e., antagonist or agonist protocol). RESULT(S): In total 2,406 women who consulted our center were included. We included 333 patients with TAI and 2019 patients without TAI. In the TAI group the crude cumulative delivery rate after six cycles was 47%, whereas the expected cumulative delivery rate was 65%. In our control the crude cumulative delivery rate after six cycles was 47%, whereas the expected cumulative delivery rate was 76%. CONCLUSION(S): Our study did not confirm an influence of TAI status in patients undergoing fertility treatment on cumulative delivery rates after six IVF/intracytoplasmic sperm injection cycles.
Asunto(s)
Enfermedades Autoinmunes/complicaciones , Autoinmunidad , Fertilización In Vitro , Infertilidad/terapia , Inyecciones de Esperma Intracitoplasmáticas , Enfermedades de la Tiroides/complicaciones , Glándula Tiroides/inmunología , Adulto , Autoanticuerpos/sangre , Autoantígenos/inmunología , Enfermedades Autoinmunes/sangre , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/inmunología , Bélgica , Biomarcadores/sangre , Implantación del Embrión , Transferencia de Embrión , Femenino , Fertilidad , Fertilización In Vitro/efectos adversos , Hospitales Universitarios , Humanos , Infertilidad/complicaciones , Infertilidad/diagnóstico , Infertilidad/fisiopatología , Yoduro Peroxidasa/inmunología , Proteínas de Unión a Hierro/inmunología , Nacimiento Vivo , Masculino , Persona de Mediana Edad , Embarazo , Índice de Embarazo , Estudios Retrospectivos , Factores de Riesgo , Inyecciones de Esperma Intracitoplasmáticas/efectos adversos , Enfermedades de la Tiroides/sangre , Enfermedades de la Tiroides/diagnóstico , Enfermedades de la Tiroides/inmunología , Hormonas Tiroideas/sangre , Resultado del Tratamiento , Adulto JovenRESUMEN
Klinefelter syndrome (KS) is the most common sex chromosomal disorder in males. Key findings in older adolescents and young men are small testes with variable hypo-androgenism, but almost universal azoospermia, most frequently in combination with a history of learning difficulties and behavior problems. Males with KS may come to medical attention through different medical presentations, given its association with several congenital malformations, and psychiatric, endocrine, and metabolic disorders. Preventive care is to be provided from diagnosis, preferentially through a multidisciplinary approach, including that from an endocrinologist, clinical psychologist or psychiatrist, neurologist, urologist, geneticist, sexologist, and a fertility team. Accurate information about the condition and assessment of associated medical conditions should be offered at diagnosis and should be followed by psychological counseling. Medical treatment during transition into adulthood is focused on fertility preservation and testosterone replacement therapy in the case of hypo-androgenism, and alleviation of current or future consequences of testicular fibrosis. However, more research is needed to determine the need for pro-active testosterone treatment in adolescence, as well as the conditions for an optimal testosterone replacement and sperm retrieval in adolescents and young men with KS. Furthermore, screening for associated diseases such as metabolic syndrome, autoimmune diseases, thyroid dysfunction, and malignancies is warranted during this period of life. The practical medical management during transition and, more specifically, the role of the endocrinologist are discussed in this article.
Asunto(s)
Manejo de la Enfermedad , Síndrome de Klinefelter/terapia , Adolescente , Composición Corporal , Neoplasias de la Mama Masculina/diagnóstico , Fertilidad/genética , Ginecomastia/terapia , Humanos , Infertilidad Masculina/terapia , Síndrome de Klinefelter/psicología , Masculino , Síndrome Metabólico/diagnóstico , Recuperación de la Esperma , Testosterona/sangre , Testosterona/uso terapéutico , Adulto JovenRESUMEN
BACKGROUND: Thyroid autoimmunity (TAI) is frequent in infertile women, but to what extent thyroglobulin autoantibodies (Tg-Abs) contribute to TAI is unclear in the literature. The aims of the present study were to determine the prevalence of TAI in women consulting for fertility problems and to investigate the impact of isolated Tg-Abs, isolated thyroid peroxidase autoantibodies (TPO-Abs), and the presence of both autoantibody types on thyroid function. Furthermore, thyroid function was compared between women with and without TAI and between infertile and fertile women. METHODS: A cross-sectional data analysis nested within an ongoing prospective cohort study was performed in order to determine the prevalence of TAI in unselected women consulting our tertiary referral center for reproductive medicine (CRM). The women underwent a determination of serum thyrotropin (TSH), free thyroxine (FT4), TPO-Abs, and Tg-Abs. The cause of infertility, age, body-mass index (BMI), and smoking habits were recorded. RESULTS: The prevalence of TAI was 16% (163/992). In 8% of cases, both types of autoantibodies were present, in 5% isolated positive Tg-Abs were found, and 4% had isolated positive TPO-Abs (p=0.025 and p=0.003 respectively). The prevalence of TAI was significantly higher in infertile women as compared to that in fertile controls (19% vs. 13%; p=0.047). The median serum TSH level was significantly higher in the women with TAI and with isolated positive Tg-Abs compared to that in women without TAI (1.83 [1.44] and 1.90 [0.85] vs. 1.47 [0.94] mIU/L; p<0.001 respectively). The median FT4, age, BMI, and smoking habits were comparable between the study groups. CONCLUSIONS: The prevalence of TAI was higher in infertile women as compared to fertile women consulting our CRM. Five percent of the women had isolated positive Tg-Abs and a significantly higher serum TSH compared to that in women without TAI.
Asunto(s)
Autoanticuerpos/sangre , Infertilidad Femenina/inmunología , Tiroglobulina/inmunología , Glándula Tiroides/inmunología , Adulto , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/epidemiología , Autoinmunidad/inmunología , Bélgica/epidemiología , Femenino , Humanos , Yoduro Peroxidasa/inmunología , Prevalencia , Tiroglobulina/sangre , Tiroxina/sangreRESUMEN
The purpose of this study is to evaluate long-term results in acromegaly patients who received surgery as first-line treatment. Repeated surgery, radiation therapy and medical treatment were considered in patients showing no postoperative remission or who suffered a relapse. Thirty-five patients suffering from acromegaly were operated on between 1993 and 2009. The patients with persistent hypersecretion received a new surgery when postoperative imaging showed localized residual lesion. The other cases with persistent hypersecretion were treated medically using dopamine agonists, somatostatin analogs or pegvisomant according to the efficiency obtained. Radiotherapy was considered when medical treatment failed to normalize hormonal hypersecretion. The overall remission rate with surgery alone was 57 % (20/35):84 % (16/19) with non-invasive adenomas and 25 % (4/16) with invasive adenomas. Fifteen patients showing no remission after surgery received additional medical and/or radiation therapy resulting in hormonal control in ten of them. Recurrences after initial postoperative remission were observed in six patients who were controlled with subsequent therapy. Using a multimodal treatment approach, the disease was brought under control in 86 % (30/35) of acromegaly patients. Surgery alone produced satisfactory initial results in non-invasive adenomas, but additional treatments were required for most of the invasive lesions.
Asunto(s)
Acromegalia/cirugía , Adenoma/cirugía , Neoplasias Hipofisarias/cirugía , Acromegalia/tratamiento farmacológico , Acromegalia/radioterapia , Adenoma/tratamiento farmacológico , Adenoma/radioterapia , Adolescente , Adulto , Anciano , Terapia Combinada , Agonistas de Dopamina/uso terapéutico , Femenino , Estudios de Seguimiento , Hormona de Crecimiento Humana/análogos & derivados , Hormona de Crecimiento Humana/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Hipofisarias/tratamiento farmacológico , Neoplasias Hipofisarias/radioterapia , Periodo Posoperatorio , Recurrencia , Retratamiento , Somatostatina/análogos & derivados , Resultado del TratamientoRESUMEN
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal-dominant cancer syndrome that is caused by a germline mutation in the MEN1 gene encoding a tumour-suppressor protein, menin. MEN1 causes a combination of endocrine tumours such as parathyroid adenomas, pituitary adenomas, glucagonomas, gastrinomas, insulinomas, adrenocortical adenomas and non-endocrine tumours. We here present a large MEN1 family where the carriers developed mild hyperparathyroidism, multiple well-differentiated functionally active neuroendocrine tumours of the pancreas and no pituitary tumour. The causal mutation is a new double substitution in the coding region of exon 2 in the MEN1 gene c.[428T>A; 429C>T], p.Leu143His. This new mutation in the MEN1 gene is clinically relevant leading to a limited penetrance and specific phenotype.
Asunto(s)
Sustitución de Aminoácidos/genética , Neoplasia Endocrina Múltiple Tipo 1/genética , Mutación/genética , Penetrancia , Proteínas Proto-Oncogénicas/genética , Adulto , Familia , Femenino , Heterocigoto , Humanos , Masculino , Linaje , FenotipoRESUMEN
A 57-year-old woman was admitted to the emergency department, presenting with episodes of altered consciousness and behaviour which, upon further examination, were linked to periods of recurrent hypoglycaemia. Imaging revealed a large mass in the right thoracic cavity while blood analysis demonstrated diminished C-peptide, (pro-)insulin, insulin-like growth factor 1 (IGF-I) and IGF binding protein 3 levels. Based on these findings, an IGF-II secreting tumour was suspected. Before the excision of the tumour, euglycaemia could only be achieved by means of intravenous glucose administration and the use of oral corticosteroids. Anatomopathologically the diagnosis of a solitary fibrous tumour (SFT) was confirmed. Immunoblot analysis on the serum revealed elevated 'big'-IGF-II levels, confirming our initial diagnosis of Doege-Potter syndrome in SFT.
Asunto(s)
Hipoglucemia/sangre , Factor II del Crecimiento Similar a la Insulina/metabolismo , Síndromes Paraneoplásicos/sangre , Tumor Fibroso Solitario Pleural/metabolismo , Diafragma/diagnóstico por imagen , Femenino , Humanos , Persona de Mediana Edad , Radiografía , Tumor Fibroso Solitario Pleural/cirugíaRESUMEN
A 16-year-old girl with a history of Graves' disease presented with two episodes of generalised tonic-clonic seizures, necessitating intensive care admission. Laboratory examination demonstrated a suppressed thyroid-stimulating hormone level with dramatically elevated free triiodothyronine, free thyroxine and thyroid-stimulating immunoglobulins. Cerebrospinal fluid analysis showed oligoclonal banding in the absence of pleocytosis, thyroid peroxidase antibodies or infection. Neuroimaging revealed the presence of a congenital arachnoid cyst in the right temporal lobe. Despite restoration of euthyroidism and administration of antiepileptic and antiviral drugs, neurological features persisted. Subsequently, intravenous corticoids were administered to exclude the contribution of an underlying autoimmune encephalopathy. The patient gradually recovered and, in retrospect, elevated serum N-methyl-D-aspartic acid-receptor (NMDA-R) antibodies were detected. Although this patient presented with an intracerebral arachnoid cyst that can act epileptogenic per se, the combination of prolonged postictal encephalopathy with unresponsiveness to antiepileptic measures, absence of focal epileptiform activity on EEG, response to corticoids and serum NMDA-R antibody positivity favours the diagnosis of autoimmune NMDA-R encephalitis in this case.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Antitiroideos/uso terapéutico , Enfermedad de Graves/complicaciones , Convulsiones/etiología , Estupor/etiología , Adolescente , Diagnóstico Diferencial , Quimioterapia Combinada , Electroencefalografía , Femenino , Enfermedad de Graves/sangre , Enfermedad de Graves/tratamiento farmacológico , Humanos , Imagen por Resonancia Magnética , Convulsiones/diagnóstico , Convulsiones/tratamiento farmacológico , Estupor/diagnóstico , Estupor/tratamiento farmacológico , Tirotropina/sangre , Tiroxina/sangreRESUMEN
Female infertility occurs in about 37% of all infertile couples and ovulatory disorders account for more than half of these. The ovaries are in continuous interaction with the other endocrine organs. The interplay may account for infertility occurring at different levels and may render the diagnosis of infertility a difficult exercise for the involved physician. A hypothalamic cause of female infertility should be considered in an appropriate clinical context, with tests pointing to a hypogonadotropic hypogonadism. It can be functional, physiological or related to organic causes. Hyperprolactinemia has well characterized effects on the normal gonadal function and treatment is well established. Acromegaly and Cushing's disease may impair fertility at different levels, mechanisms involved however remain ill defined. Thyroid disorders, both hyperthyroidism and hypothyroidism, can interact with the ovaries, through a direct effect on ovarian function, but autoimmunity may be involved, as well as alterations of the sex hormone binding protein levels. Primary ovarian disorders, such as the polycystic ovary syndrome and primary ovarian insufficiency are frequent diseases, for which novel treatments are currently being developed and discussed. We will propose an algorithm for the diagnosis and approach of the female patient presenting with infertility on the basis of the available evidence in literature.
Asunto(s)
Hipogonadismo/complicaciones , Infertilidad Femenina/etiología , Enfermedades del Ovario/complicaciones , Amenorrea/complicaciones , Síndrome de Cushing/complicaciones , Femenino , Humanos , Enfermedades Hipotalámicas/complicaciones , Infertilidad Femenina/diagnóstico , Masculino , Neoplasias Hipofisarias/complicaciones , Prolactinoma/complicaciones , Enfermedades de la Tiroides/complicacionesRESUMEN
OBJECTIVE: To investigate the impact of ovarian hyperstimulation syndrome (OHSS) on thyroid function in women without thyroid disorders and to compare it with that in women with uncomplicated controlled ovarian hyperstimulation (COH). DESIGN: Retrospective analysis. SETTING: Tertiary referral fertility center. PATIENT(S): A total of 77 women undergoing COH of whom 25 developed OHSS and 52 had no OHSS. Women with the presence of thyroid disorders were excluded, and only women pregnant after assisted reproductive technology were included. INTERVENTION(S): Serum TSH and free T4 (fT4) levels were measured before and 2, 4, and 6 weeks after embryo transfer (ET), and thyroid peroxidase and thyroglobulin antibody levels were measured before ET to exclude thyroid autoimmunity. The diagnosis of OHSS was based on clinical, ultrasonographic, and biologic features. MAIN OUTCOME MEASURE(S): Thyroid function, OHSS. RESULT(S): Serum TSH and fT4 levels increased 2 weeks after ET in both study groups compared with prestimulation levels. In the OHSS group: TSH, 1.9 ± 0.8 mIU/L vs. 3.1 ± 1.9 mIU/L; fT4, 12.3 ± 1.4 ng/L vs. 13.4 ± 2.1 ng/L. In the no-OHSS group: TSH, 2.1 ± 1.1 mIU/L vs. 2.6 ± 1.9 mIU/L; fT4, 13.0 ± 1.7 ng/L vs. 13.8 ± 1.6 ng/L. The increment was comparable between both study groups. CONCLUSION(S): Serum TSH levels increased significantly after COH in a comparable way in both study groups, when no thyroid disorders were present.